Giants join forces: Genetic diagnostic tests for cancer
Illumina announced a partnership with Merck (NYSE:MRK) to develop and commercialize genetic mutation tests to identify homologous recombination defects (HRD).
The HRD test will utilize Illumina's TruSight Oncology 500.
Illumina will develop a new HRD CDX trial for the European Union and the United Kingdom to help identify ovarian cancer patients with positive HRD status who are eligible for treatment with LyPARZA (OlAPARIB), jointly developed and commercialized by Merck and Astrazeneca.
In addition, Illumina will develop and commercialize an INVESTIGation-only (RUO) HRD analysis as an addition to the TSO 500 RUO. Illumina plans to launch the product globally, excluding the US and Japan.
Illumina recently acquired GRAIL, the developer of the Galleri blood test, which can detect 50 different cancers before symptoms appear. $Illumina(ILMN.US$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
